Type I interferon biomarker in idiopathic inflammatory myopathies: associations of Siglec-1 with disease activity and treatment response
Siglec-1 was increased in treatment-naive IIM patients and showed a decline after IVIG monotherapy. In DM, Siglec-1 expression correlated with relevant clinical measures. This underlines the dynamic role of type I IFN in IIM and the biomarker potential of Siglec-1, in particular in DM. These findings should be further validated in larger cohorts with longer follow-up.
Authors
- Joost Raaphorst (ORCID: https://orcid.org/0000-0002-3658-2001)
- Marc H.A. Jansen (ORCID: https://orcid.org/0000-0001-6969-8759)
- Sanne W Evers
- Renske G Kamperman (ORCID: https://orcid.org/0000-0001-9369-1127)
- Femke van Wijk (ORCID: https://orcid.org/0000-0001-8343-1356)
- Annet van Royen‐Kerkhof (ORCID: https://orcid.org/0009-0009-6874-4421)
- Anneke J. van der Kooi (ORCID: https://orcid.org/0000-0002-5261-5512)
- Ivo van Schaik
- Saskia R Veldkamp (ORCID: https://orcid.org/0000-0002-1626-353X)
- Johan Lim (ORCID: https://orcid.org/0000-0002-7565-1954)
Institutions
- University Medical Center Utrecht (NL)
- Sanquin (NL)
- Amsterdam University Medical Centers (NL)
- Wilhelmina Children's Hospital (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/rheumatology/keae630
- Citations
- 10
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 3.87
Funders
- CSL Behring